

Who?



Having a certain chronic condition and RSV can have severe consequences

While you may be doing everything you can to stay healthy, RSV can still take you by surprise. RSV is a contagious virus that can **severely impact older adults, particularly those with certain chronic conditions like diabetes, asthma, COPD, or CHF.**^{1,2,4-5}

CHF=chronic heart failure; COPD=chronic obstructive pulmonary disease; RSV=respiratory syncytial virus.

What?

Questions to ask your doctor about RSV

- As someone who is aged 60 years or older with a certain chronic condition, what should I know about my risk of RSV?
- As someone who is aged 50-59 years old with a certain chronic condition, what should I know about my risk of RSV?
- How could RSV impact my chronic condition?
- Can RSV increase the risk of hospitalization because of certain chronic conditions, like mine?
- Can RSV lead to pneumonia?
- Should I get vaccinated for RSV?

It only takes a minute to speak to your doctor about your risk of RSV and how to prevent it.

In a New Zealand study, RSV hospitalisation rates were significantly higher among older adults with certain underlying conditions.* In older adults aged 65–80 years old with COPD, the rate of RSV-hospitalisation was around 10x higher compared with those without COPD.*¹



Now's the time

Talk to your doctor today about RSV.

Help protect yourself with

AREXVY³

ASK your doctor if AREXVY is right for you.

Vaccination may not protect all recipients.³ AREXVY should not be administered if you are allergic to any of its ingredients.³

AREXVY is indicated only for adults 60+ years old and adults 50-59 years old at increased risk for RSV disease. Data presented is not intended to imply efficacy beyond RSV-related lower respiratory tract disease prevention.³

*A population-based surveillance of acute respiratory illness hospitalisations was linked to national administrative data to estimate seasonal RSV hospitalisation rates among adults aged 18-80 years with the following preexisting chronic medical conditions: COPD, asthma, congestive heart failure, coronary artery disease, cerebrovascular accidents, diabetes mellitus and end-stage renal disease. Among 883,999 adult residents aged 18-80 years, 281 RSV-positive hospitalisations were detected during 2012-2015 winter seasons.¹

Reference: 1. Prasad N, Walker TA, et al. Clin Infect Dis. 2021 Jul 1;73(1):e158-e163 2.CDC;2024;1-2:RSV in Adults 3.GlaxoSmithKline New Zealand. AREXVY Data Sheet. GSK NZ;2025.

4. Papi A;N Engl J Med;2023;388;595-608 5. Mesa-Frias, M;J Manag Care Spec Phar;2022;1-13

AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older, and in adults 50 through 59 years of age who are at increased risk of RSV disease. **AREXVY is a prescription medicine; it is not funded and charges will apply.** A single dose (0.5 mL) contains 120 micrograms of RSVPreF3 antigen adjuvanted with AS01E, composed of the plant extract *Quillaja saponaria* Molina, fraction 21 (QS-21) (25 micrograms) and 3-O-desacetyl-4'-monophosphoryl lipid A (MPL) from *Salmonella minnesota* (25 micrograms). **AREXVY should not be administered** if you are allergic to any component of this vaccine. **AREXVY has risks and benefits – ask your doctor if AREXVY is right for you. Use strictly as directed. Side effects include:** joint pain, injection site reactions including pain, swelling and redness, headache, runny nose, fatigue, fever and chills. This is not a full list. Vaccination with AREXVY may not fully protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. Normal doctor's charges apply. **Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz.** Trademarks are owned by or licensed to the GSK group of companies. ©2026 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. **Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.** TAPS NP24335-PM-NZ-RSA-LBND-260003 | Date of approval: 03.2026 | Date of expiry: 03.2028